Feuerstein Comments on Antigenics: Weak at Best 15 comments
August 06, 2009
| about: AGEN
Submit
an article to
an article to
-
Font Size:
-
Print
- TweetThis
Adam Feuerstein's video message of why Antigenics (AGEN) stinks is another fine example of why the small investor should not trust the big boys to look out for them. Anyone paying a subscription to the sham of an organization known as "The Street.com", shame on you. They have an agenda, and it has nothing to do with making you money.
They must have really missed the boat on Antigenics, because not only did they send Adam Feuerstein to bash the stock, but they sent his message via video! Their determination to 'protect' the small investor is impressive, huh?
I'm actually quite surprised that Feuerstein put himself in the position that he has because this time, more than any before, he may have put a hold in his credibility that he won't be able to recover from.
The first major flaw in Adam's argument against Antigenics came when he 'advised' investors to be wary of calling Antigenics the next Dendreon (DNDN) because, I quote from his video, "I know Dendreon, and Antigenics isn't even close."
Let's get something straight: Feuerstein completely missed the boat on Dendreon. At no point did Adam ever give Provenge, Dendreon or the company's stock a chance. He called it wrong the entire way. In fact, while bashing DNDN, he said many of the same things about Dendreon and Provenge that he just said about Antigenics and Oncophage.
Americans may have short memories, but VFC's Stock House does not. Feuerstein was dead wrong with Dendreon and I'm very surprised that he would have the audacity to imply otherwise. If anything, in using his knowledge of Dendreon as an example of his record on cancer immunotherapies, he just made a stronger case for Antigenics. Adam's number one point was the fact that Oncophage doesn't work, after failing every late stage trial that tested its efficacy.
Here's a fine example of how the big boys work: they'll mislead you without giving you all the facts. Oncophage and many other cancer immunotherapy treatments, including Provenge, were failing late stage trials until the end-mark became overall survivability. The ASCO conference this year was a huge stepping stone for cancer immunotherapies because the evidence presented proved that the longer patients receive the treatment, the better the vaccines work.
In the case of Antigenics, patients that received the vaccine earlier on in disease progression showed the most benefit. It's been widely argued that the earlier a patient receives a cancer vaccine, the more beneficial the treatment will be for the patient. So, while Feuerstein may say that Oncophage does not work, the treatment actually helped make the case that the treatments need to be used earlier.
Adam's point number two was that Oncophage in Russia will not sell. At this point that is an opinion, but he does his best to portray it as a fact... If the fact that Oncophage won't sell in Russia is his big argument, I'll say duly noted, Adam, but so far your credibility with cancer vaccines has no standing.
Next he notes that Oncophage has a "minuscule" chance of getting approval there; another personal opinion that is not backed up with facts or data as to why he holds that opinion. When dealing with opinions, a person's credibility is what gives weight to the words, and if that is the case, his words are as light as a feather.
His last point was backed up by his nice crayon-caliber chart showing the decline in Antigenics' stock price. That was his ONLY piece of evidence to back up his claim that 'smart money' is not buying the stock.
The man must assume that everyone is an idiot because at no other point in the company's history were they ready to launch a cancer vaccine into the market anywhere. At no other time in the company's history was Oncophage submitted for approval with the EMEA and at no other time in the company's history was Oncophage showing excellent long term survivability results, so of course the stock price is going rise now.
And for Adam's GLARING OMISSION, he said nothing about QS-21. Nothing. You can't do justice to the company or its stock without mentioning QS-21. Period.
But his point was not to inform you about the company, it was to get you to sell your shares because he, and whoever he is really 'working' for, has completely missed the boat up until this point. Wednesday morning was another perfect example of why you can't trust the big boys to look out for you.
Adam Feuerstein's manipulative, non-informational and script-read stuttering piece about Antigenics was, in my opinion, a demonstration of how low the standards of public media have become; and it did wonders to expose the true motivations of the Street.com to try and keep the small investor stupid and uninformed.
In my opinion, the guys that Adam really works for were short AGEN, probably based on his recommendation, and now they're sending him out in an attempt to manipulate the stock down so that they can cover. He did look a little rattled on Wednesday morning, like he hadn't gotten much sleep. Probably because he realizes that he got AGEN dead wrong, just like DNDN.
Disclosure: VFC is long AGEN.
I'm actually quite surprised that Feuerstein put himself in the position that he has because this time, more than any before, he may have put a hold in his credibility that he won't be able to recover from.
The first major flaw in Adam's argument against Antigenics came when he 'advised' investors to be wary of calling Antigenics the next Dendreon (DNDN) because, I quote from his video, "I know Dendreon, and Antigenics isn't even close."
Let's get something straight: Feuerstein completely missed the boat on Dendreon. At no point did Adam ever give Provenge, Dendreon or the company's stock a chance. He called it wrong the entire way. In fact, while bashing DNDN, he said many of the same things about Dendreon and Provenge that he just said about Antigenics and Oncophage.
Americans may have short memories, but VFC's Stock House does not. Feuerstein was dead wrong with Dendreon and I'm very surprised that he would have the audacity to imply otherwise. If anything, in using his knowledge of Dendreon as an example of his record on cancer immunotherapies, he just made a stronger case for Antigenics. Adam's number one point was the fact that Oncophage doesn't work, after failing every late stage trial that tested its efficacy.
Here's a fine example of how the big boys work: they'll mislead you without giving you all the facts. Oncophage and many other cancer immunotherapy treatments, including Provenge, were failing late stage trials until the end-mark became overall survivability. The ASCO conference this year was a huge stepping stone for cancer immunotherapies because the evidence presented proved that the longer patients receive the treatment, the better the vaccines work.
In the case of Antigenics, patients that received the vaccine earlier on in disease progression showed the most benefit. It's been widely argued that the earlier a patient receives a cancer vaccine, the more beneficial the treatment will be for the patient. So, while Feuerstein may say that Oncophage does not work, the treatment actually helped make the case that the treatments need to be used earlier.
Adam's point number two was that Oncophage in Russia will not sell. At this point that is an opinion, but he does his best to portray it as a fact... If the fact that Oncophage won't sell in Russia is his big argument, I'll say duly noted, Adam, but so far your credibility with cancer vaccines has no standing.
Next he notes that Oncophage has a "minuscule" chance of getting approval there; another personal opinion that is not backed up with facts or data as to why he holds that opinion. When dealing with opinions, a person's credibility is what gives weight to the words, and if that is the case, his words are as light as a feather.
His last point was backed up by his nice crayon-caliber chart showing the decline in Antigenics' stock price. That was his ONLY piece of evidence to back up his claim that 'smart money' is not buying the stock.
The man must assume that everyone is an idiot because at no other point in the company's history were they ready to launch a cancer vaccine into the market anywhere. At no other time in the company's history was Oncophage submitted for approval with the EMEA and at no other time in the company's history was Oncophage showing excellent long term survivability results, so of course the stock price is going rise now.
And for Adam's GLARING OMISSION, he said nothing about QS-21. Nothing. You can't do justice to the company or its stock without mentioning QS-21. Period.
But his point was not to inform you about the company, it was to get you to sell your shares because he, and whoever he is really 'working' for, has completely missed the boat up until this point. Wednesday morning was another perfect example of why you can't trust the big boys to look out for you.
Adam Feuerstein's manipulative, non-informational and script-read stuttering piece about Antigenics was, in my opinion, a demonstration of how low the standards of public media have become; and it did wonders to expose the true motivations of the Street.com to try and keep the small investor stupid and uninformed.
In my opinion, the guys that Adam really works for were short AGEN, probably based on his recommendation, and now they're sending him out in an attempt to manipulate the stock down so that they can cover. He did look a little rattled on Wednesday morning, like he hadn't gotten much sleep. Probably because he realizes that he got AGEN dead wrong, just like DNDN.
Disclosure: VFC is long AGEN.
Related Articles
|
-
The Seeking Alpha 100
See allThe top 100 stock
market authors
selected for publication
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most active
Instabloggers.-
1
David Fry
-
2
TraderMark
-
3
Don Dion
-
4
Cliff Wachtel
-
5
Mike Havrilla
Top Instabloggers » -
1
-
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
Adam F. (AF) & thestreet.com appear to be manipulative organizations as you suggest as many other people also believe and lets not forget AF also missed HGSI and MEDX plus several others.
May I suggest you eMail your article to the SEC, I hope SH also also does.
You ans SH have a lot of backers on this article.
Just something to think about.
AGEN, on the other hand, has a compound which has been shown to work.
He has been wrong in predicting most all FDA approvals and top-line data results. But that's nearly impossible anyway, given that the only way to know is to have the raw data and run it through a stat program and generate a P-value. If we could all do that, biotech prices wouldn't be a mystery.
The Big Boys could be any of the above mentioned. In my opinion, they're a bunch of Cramer's old hedge fund cronies, but that is only my speculation. For I know, you could be one them! The fact of the matter is, these guys play their manipulative games at the expense of the small investor. That doesn't sit well with VFC.
Even more importantly, these guys are playing their games with a company's stock when the company is producing a drug that has been proven to extend the life of cancer patients- with no side effects. That also doesn't sit well with VFC. We all like to make a few extra bucks, but these guys will do or destroy anything for their own financial gain. I don't like that.
But that's just me.
To answer your second question, It's obvious that you haven't read much of my stuff to even ask that question.
Thanks for the interest.
VFC
On Aug 06 11:51 AM Robert0713 wrote:
> Let's not mix apples and oranges. AF is right about HEB, ampligen,
> and Carter. It's a 30 year old compound Carter has been trying to
> find a disease for the whole time. CFS??? Not even defined. The
> other nonsense is all documented in his articles. You can read them
> yourself.
>
> AGEN, on the other hand, has a compound which has been shown to work.
>
>
> He has been wrong in predicting most all FDA approvals and top-line
> data results. But that's nearly impossible anyway, given that the
> only way to know is to have the raw data and run it through a stat
> program and generate a P-value. If we could all do that, biotech
> prices wouldn't be a mystery.